Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(112 produits)
- CSF-1R(42 produits)
- EGFR(572 produits)
- Récepteur Ephrin(23 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(169 produits)
- SON(5 produits)
- Hck(3 produits)
- IGF-1R(87 produits)
- PDGFR(126 produits)
- PYK2(7 produits)
- Src(79 produits)
- Récepteur TAM(32 produits)
- Tie-2(20 produits)
- Récepteur Trk(59 produits)
- Tyrosine Kinases(26 produits)
- VEGFR(268 produits)
- c-Fms(108 produits)
- c-Kit(101 produits)
- c-Met/HGFR(128 produits)
- c-RET(51 produits)
Affichez 13 plus de sous-catégories
1372 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45TrkC-IN-1
CAS :<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395BIIB129
CAS :<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Formule :C19H22N6O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :366.42DDR1-IN-10
CAS :<p>DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.</p>Formule :C24H25F4N5O2Couleur et forme :SolidMasse moléculaire :491.481NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64TrkA-IN-7
CAS :<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Formule :C16H13N3O3Couleur et forme :SolidMasse moléculaire :295.293JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54TRK-IN-26
CAS :<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Formule :C30H22F2N6O4Couleur et forme :SolidMasse moléculaire :568.53Lucitanib dihydrochloride
CAS :<p>Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.</p>Formule :C26H27Cl2N3O4Couleur et forme :SolidMasse moléculaire :516.42PET-cGMP
CAS :<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Formule :C18H16N5O7PCouleur et forme :SolidMasse moléculaire :445.323HER2-IN-6
CAS :<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58AMG-25
CAS :<p>AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.</p>Formule :C23H17N5O2Degré de pureté :98.16%Couleur et forme :SolidMasse moléculaire :395.41HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424EGFR-IN-38
CAS :<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98Sacibertinib
CAS :<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08VEGFR2-IN-1
CAS :<p>VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.</p>Formule :C22H18N6SDegré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :398.48EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39BNN-20
CAS :<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Formule :C20H30O2Couleur et forme :SolidMasse moléculaire :302.45DDR1-IN-8
CAS :<p>DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.</p>Formule :C23H24F3N5O2Masse moléculaire :459.46HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formule :C12H14N4OS2Couleur et forme :SolidMasse moléculaire :294.4EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formule :C24H15FO3Couleur et forme :SolidMasse moléculaire :370.37c-Fms-IN-15
CAS :<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>Formule :C29H28F3N7O2Masse moléculaire :563.57Protein kinase inhibitor 4
CAS :<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Formule :C25H24F2N6O3SMasse moléculaire :526.56CL-A3-7
CAS :<p>CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.</p>Formule :C24H22Br2F2N2O3Couleur et forme :SolidMasse moléculaire :584.252-Methyl-3-phenylquinoxaline
CAS :<p>2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).</p>Formule :C15H12N2Couleur et forme :SolidMasse moléculaire :220.27EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33FGFR-IN-16
CAS :<p>FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.</p>Formule :C30H27Cl2N7O4Couleur et forme :SolidMasse moléculaire :620.49EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Couleur et forme :SolidFGFR4-IN-4
CAS :<p>FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.</p>Formule :C28H32Cl2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :603.5G-744
CAS :<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Formule :C29H29N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.64EGFR-IN-126
CAS :<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45TAS05567
CAS :<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Formule :C21H29N9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.518-Br-cGMP-AM
CAS :<p>8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.</p>Formule :C13H15BrN5O9PCouleur et forme :SolidMasse moléculaire :496.16EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27DYRKs-IN-1
CAS :<p>DYRKs-IN-1 has antitumor activity.</p>Formule :C30H30ClN7O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :588.06TRK-IN-28
CAS :<p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>Formule :C27H25F2N7Couleur et forme :SolidMasse moléculaire :485.53AZ12601011
CAS :<p>AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.</p>Formule :C19H15N5Degré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :313.36Vecabrutinib
CAS :<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Formule :C22H24ClF4N7O2Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :529.92
